Comparison of Anti-Spike Reactivity and nAb Titers in Plasma Used in REMAP-CAP and Argentina Trials
We compared anti-spike IgG (S-IgG) reactivities of plasma included or excluded from trial use based on reactivity to spike protein with an in-house ELISA. For the REMAP-CAP panel, plasma included in the clinical trial showed a 5.2-fold higher geometric mean titer (GMT) of S-IgG than excluded plasma (GMTs of 1952 and 372, respectively; 